A randomized multicentre controlled study of 240 cardiac surgery patients at high risk of acute kidney injury (AKI) has demonstrated that remote ischaemic preconditioning can reduce the rate of AKI and requirement for renal replacement therapy. These findings suggest this procedure could be a promising therapeutic option for this high-risk patient group.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rosner, M. H. & Okusa, M. D. Acute kidney injury associated with cardiac surgery. Clin. J. Am. Soc. Nephrol. 1, 19–32 (2006).
Zarbock, A. et al. Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial. JAMA 313, 2133–2141 (2015).
Suzuki, T. Zur morphologie der nierensekretion unter physiologischen und pathologischen bedingungen [German]. Jena: Fischer (1912).
Zager, R. A. 'Biologic memory' in response to acute kidney injury: cytoresistance, toll-like receptor hyper-responsiveness and the onset of progressive renal disease. Nephrol. Dial. Transpl. 28, 1985–1993 (2013).
Bonventre, J. V. Kidney ischemic preconditioning. Curr. Opin. Nephrol. Hypertens. 11, 43–48 (2002).
Bonventre, J. V. Limb ischemia protects against contrast-induced nephropathy. Circulation 126, 384–387 (2012).
Przyklenk, K. et al. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 87, 893–899 (1993).
Tapuria, N. et al. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury—a review. J. Surg. Res. 150, 304–330 (2008).
Wu, H. et al. Preconditioning with recombinant high-mobility group box 1 protein protects the kidney against ischemia-reperfusion injury in mice. Kidney Int. 85, 824–832 (2014).
Acknowledgements
The research in the laboratory of J.V.B. is supported by grants DK39773 and DK72381 awarded by the NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.V.B. consults on AKI for Astellas Pharma, AbbVie, and Takeda and consults and holds equity in MediBeacon, Sentien Biotechnologies, Inc., and Thrasos Therapeutics. J.V.B. is a co-inventor on KIM-1 patents assigned to Partners HealthCare and licensed to Johnson & Johnson, Sekisui Diagnostics LLC, Novartis, Biogen IDEC, and Astute Medical. He has received grant support from Novo Nordisk and Roche. A.Z. declares no competing interests.
Rights and permissions
About this article
Cite this article
Zuk, A., Bonventre, J. Can remote ischaemic preconditioning prevent AKI?. Nat Rev Nephrol 11, 512–513 (2015). https://doi.org/10.1038/nrneph.2015.119
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2015.119
This article is cited by
-
Assessing renal changes after remote ischemic preconditioning (RIPC) of the upper extremity using BOLD imaging at 3T
Magnetic Resonance Materials in Physics, Biology and Medicine (2018)